DexCom Reports Record Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2017 and Provides Initial 2018 Outlook
DexCom, Inc. (Nasdaq: DXCM), the leader in continuous glucose monitoring
(„CGM”), today reported that it achieved preliminary, unaudited revenue
of approximately $218 million for the fourth quarter ended December 31,
…
DexCom, Inc. (Nasdaq: DXCM), the leader in continuous glucose monitoring
("CGM”), today reported that it achieved preliminary, unaudited revenue
of approximately $218 million for the fourth quarter ended December 31,
...